Diffusion Pharmaceuticals Inc
NASDAQ:CRVO
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
6.32
25.93
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CRVO stock under the Base Case scenario is 9.38 USD. Compared to the current market price of 12.54 USD, Diffusion Pharmaceuticals Inc is Overvalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Diffusion Pharmaceuticals Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CRVO cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Diffusion Pharmaceuticals Inc
Balance Sheet Decomposition
Diffusion Pharmaceuticals Inc
Current Assets | 10m |
Cash & Short-Term Investments | 7.8m |
Receivables | 915.4k |
Other Current Assets | 1.3m |
Non-Current Assets | 7.8k |
Other Non-Current Assets | 7.8k |
Current Liabilities | 2.6m |
Accounts Payable | 662.5k |
Accrued Liabilities | 1.9m |
Earnings Waterfall
Diffusion Pharmaceuticals Inc
Revenue
|
9.7m
USD
|
Operating Expenses
|
-20.4m
USD
|
Operating Income
|
-10.8m
USD
|
Other Expenses
|
5.7m
USD
|
Net Income
|
-5m
USD
|
Free Cash Flow Analysis
Diffusion Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
CRVO Profitability Score
Profitability Due Diligence
Diffusion Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
Score
Diffusion Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.
CRVO Solvency Score
Solvency Due Diligence
Diffusion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Score
Diffusion Pharmaceuticals Inc's solvency score is 80/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CRVO Price Targets Summary
Diffusion Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for CRVO is 58.75 USD with a low forecast of 35.35 USD and a high forecast of 73.5 USD.
Dividends
Current shareholder yield for CRVO is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Diffusion Pharmaceuticals Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Charlottesville, Virginia and currently employs 16 full-time employees. The company went IPO on 2016-11-09. Diffusion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development of therapies that enhance the body’s ability to deliver oxygen to the areas where it is needed. The Company’s product candidate, Trans Sodium Crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia. The firm is focused on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors. Hypoxia is associated with the pathophysiology of many acute and chronic conditions including cancers, heart attack, stroke, ARDS, skin and soft tissue diseases, neurodegenerative diseases and other intractable and difficult-to-treat conditions, further complicating treatment of the underlying condition by medical providers.
Contact
IPO
Employees
Officers
The intrinsic value of one CRVO stock under the Base Case scenario is 9.38 USD.
Compared to the current market price of 12.54 USD, Diffusion Pharmaceuticals Inc is Overvalued by 25%.